

Earnings Release

1Q22



Animal Health Award Winner 2021



Disclaimer

This presentation brings statements about future events that are subject to risks and uncertainties. Such statements are based on our Management's beliefs and assumptions and on information that the Company currently has access to. Statements about future events include information regarding our intentions, beliefs or current expectations, as well as those of the members of the Management Board and Company Directors.

Disclaimers according to the statements and the information about the future also include information about possible or presumed operating results, as well as statements preceded by, followed by or that include the words "believes", "may", "will", "continue", "expects", "anticipates", "intends", "plans", "estimates" or similar expressions.

The statements and information are not guarantees of future performance. They involve risks, uncertainties and assumptions because they are related to future events and, therefore, depending on circumstances that may or may not occur. Future results and value creation for our shareholders may differ materially from those expressed or implied by the statements made about the future. Many of the factors that will determine these results and values are beyond our ability to control or predict.

On today's call



Kleber Gomes
CEO

Marcelo Silva
*Chief financial and investor
relations officer*

Destaque



Ourofino Day

Done 100%
online and in
house



GPTW

In 2022 we were
once again certified
as a “Great Place
to Work” company



Regenera

Startup
acquisition
closing



NeoStem

First launch of
the year, as a
result of our
M&A



NeoStem

Canine Mesenchymal stem cells

NeoStem is a stem cell product with innovative technology, different from conventional therapeutic protocols, indicated for osteoarthritis, distemper sequel and dry keratoconjunctivitis.

iuse.
• *saber*

Launch

19/5 - 19h30

(Brasília time)

Destques Financeiros



Net revenue in 1Q22 grows 19.9% to R\$ 202.3 million



Adjusted EBITDA reached R\$ 28.9 million in 1Q22, 15.1% growth



Adjusted net income of R\$ 13.9 million in 1Q22



Leverage of 1.4x EBITDA, including debt cost at 9.2% per year and 78% of the long-term debt.




Consolidated Results


Net Revenue and Gross Profit

R\$ Million

Net Revenue



Gross Profit and Gross Margin



Net revenue

Keeps growing strong, 19.9% over a base that grew 51% last year.

Gross margin


Still stable despite the challenging scenario of inflation, and pressure supply chain

Production Animals


Net Revenue and Gross Profit R\$ Million

Strong revenue and margin growth guided by volume and price gains. Highlight for “IATF” protocols and antiparasitic lines

Net Revenue



Gross Profit and Gross Margin




Companion Animals

Net Revenue and Gross Profit R\$ Million


Net revenue

Maintaining a growth trend and a slight drop in gross margin due to the impact of a less favorable mix

Net Revenue



Gross Profit and Gross Margin



International Operations


Growth

In local currency, both in volume and price. Strong appreciation of the Brazilian Real impacted gross margin


Net Revenue and Gross Profit

R\$ Million

Net Revenue




Gross Profit and Gross Margin



Adjusted EBITDA

R\$ Millions

We keep growing on top of a base that grew 383% in 1Q21 compared to 1Q22, despite cost pressures offsetting the dilution of SG&A



P&D and SG&A


R\$ Million

P&D

Higher investments in initial cycles to development new products


SG&A

We presented a reduction of 1.6 p.p compared to 1Q21, reflecting management efforts aimed at continuous improvement of administrative and industrial processes



Cash Generation

R\$ Milhões




Investments

In the coverage of inventories and acquisitions

Capital Structure

Debt remains stable with 78% of long-term debt and 28% of total gross debt with a term of more than 5 years



Capital Structure

Bank indebtedness aging R\$ Millions

■ Short Term ■ Long Term




Investments in R&D

R\$ Milhões

Investments in R&D

Reached 9% of net revenue, totaling R\$18.1 million, an increase of 19% compared to 1Q21



Doubts?



**Ourofino Saúde Animal
Participações S.A. (B3: OFSA3)**
Investors Relations



ri@ourofino.com



(16) 3518-2000



ir.ourofino.com

